Drug
Elagolix clinical trials
Also written ABT-620, NBI-56418 and Orlissa.
- studies test it
- 31
- open now
- 3
- in phase 3
- 13
- first study started
- 2005
Keep track of what changes. Save the elagolix studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Brand
Studies by the year they started
31 studies that test it; most in 2022 (4)
| Year | Studies |
|---|---|
| 2005 | 1 |
| 2006 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2011 | 2 |
| 2012 | 2 |
| 2013 | 2 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2019 | 3 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 4 |
| 2023 | 1 |
| 2024 | 1 |
| 2025 | 1 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 2
- Phase 1
- 1
- Phase 2
- 9
- Phase 3
- 13
- Phase 4
- 6
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 21 · Other 10
AbbVie (15) · Yale University (3) · AbbVie (prior sponsor, Abbott) (3) · Nanjing Chia-tai Tianqing Pharmaceutical (1) · Colorado Center for Reproductive Medicine (1) · Wake Forest University Health Sciences (1) · Abbott (1) · Pak Emirates Military Hospital (1)
Often tested with
Tested in the same studies.
Estradiol (5) · Norethindrone Acetate (5) · Norethindrone (5) · Contraceptives, Oral (1)
Studies
Open first, then newest update. How each study uses elagolix is read from its arms, and is right about nine times in ten.
Testing it · 31
- Role of Menopause in ThermoregulationRecruitingPhase 4Penn State UniversityNCT06798571Written as Elagolix Oral Tablet
- Brain and Blood Vessel Health Following Endometriosis Treatment in People With EndometriosisNot yet recruitingPhase 4Colorado State UniversityNCT07799246Written as Investigate how Orlissa, a commonly used medication used to treat symptoms of endometriosis, impact biomarkers of brain health
- Comparison of Elagolix and OCPs in Reducing Endometriosis Associated Pelvic PainEnrolling by invitationPhase 4Pak Emirates Military HospitalNCT07532876Written as Elagolix
- Cardiovascular Disease Risk in Women With EndometriosisCompletedEarly Phase 1Yale UniversityNCT03746535Written as Elagolix
- Study Of Oral Elagolix Tablets In Combination With Combined Oral Contraceptive Capsules/Tablets To Assess Dysmenorrhea Response In Adult Female Participants With Endometriosis And Associated Moderate To Severe PainActive, not recruitingPhase 3AbbVieNCT04333576Written as Elagolix
- Pre-IVF Treatment With a GnRH Antagonist in Women With EndometriosisCompletedPhase 3Yale UniversityNCT04173169Written as Elagolix 200 MG
- Pre-IVF Treatment With a GnRH Antagonist in Women With endometriosis_tempActive, not recruitingPhase 3Yale UniversityNCT06375811Written as Elagolix 200 MG
- A Clinical Trial to Evaluate Efficacy and Safety of Elagolix Tablets in Women With Moderate or Severe Endometriosis-associated PainCompletedPhase 3Nanjing Chia-tai Tianqing PharmaceuticalNCT06076486Written as Elagolix
- Long-Term Safety Study of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal WomenCompletedPhase 3AbbVieNCT03271489Written as Elagolix
- An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to Adrenal Adenomas in Postmenopausal WomenTerminatedPhase 4Icahn School of Medicine at Mount SinaiNCT05038878Written as Elagolix
- Comparison Elagolix vs Depot Leuprolide Prior to Frozen Embryo Transfers in Patients With EndometriosisCompletedEarly Phase 1Colorado Center for Reproductive MedicineNCT04445025Written as Elagolix 200 MG
- A Clinical Study to Evaluate the Safety and Efficacy of Elagolix in Participants With Moderate to Severe Endometriosis-Associated PainCompletedPhase 3AbbVieNCT03213457Written as Elagolix
- Elagolix for Fertility Enhancement Clinical TrialCompletedPhase 2Wake Forest University Health SciencesNCT04039204Written as Elagolix
- A Study to Evaluate Safety and Efficacy of Elagolix in Patients With Moderate to Severe Endometriosis-Associated PainStatus unknownPhase 3Qilu Pharmaceutical (Hainan) Co., Ltd.NCT05648669Written as Elagolix
- Study of the Safety and Efficacy of Elagolix in Women With Polycystic Ovary SyndromeCompletedPhase 2AbbVieNCT03951077Written as Elagolix
- A Study to Evaluate the Safety and Efficacy of Elagolix for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal WomenCompletedPhase 4AbbVieNCT03886220Written as Elagolix
- Efficacy and Safety of Elagolix in Combination With Estradiol/Norethindrone Acetate for the Management of Heavy Menstrual Bleeding Associated With Uterine Fibroids in Premenopausal Women (Replicate Study)CompletedPhase 3AbbVieNCT02691494Written as Elagolix
- Safety and Efficacy of Elagolix in Pre-Menopausal Women With Heavy Uterine Bleeding and Uterine FibroidsCompletedPhase 2AbbVie (prior sponsor, Abbott)NCT01441635Written as Elagolix
- Global Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Women With Moderate to Severe Endometriosis-associated PainCompletedPhase 3AbbVieNCT02143713Written as Elagolix
- Study to Evaluate the Long-Term Safety and Efficacy of Elagolix in Adults With Moderate to Severe Endometriosis-Associated PainCompletedPhase 3AbbVieNCT01760954Written as Elagolix
See all 31 studies that test elagolix →
Given in every arm · 3 — elagolix is usual care beside what is tested
- Brain Blood Flow Responses to Stress: Sex DifferencesCompletedPhase 4University of Wisconsin, MadisonNCT06253702Written as Orilissa
- An Extension Study to Evaluate the Efficacy and Safety of Elagolix in Premenopausal Women With Heavy Menstrual Bleeding Associated With Uterine FibroidsCompletedPhase 3AbbVieNCT02925494Written as Elagolix
- A Study to Evaluate Safety and Efficacy of Elagolix in Participants With Endometriosis With Associated Moderate to Severe PainTerminatedPhase 3AbbVieNCT03343067Written as elagolix
As the comparator · 1 — what is tested is compared with elagolix
Codes
What other systems call elagolix · ClinicalTrials.gg INT005405
- MeSH (NLM) C539351elagolixOne source NLM
- UNII (FDA) 5B2546MB5ZELAGOLIXConfirmed FDA, NLM, Wikidata
- RxNorm 2049846One source FDA
- Wikidata Q21098999elagolixConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C153373ElagolixOne source FDA
- DrugBank DB11979One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C539351 | elagolix | One source NLM |
| UNII (FDA) | 5B2546MB5Z | ELAGOLIX | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2049846 | — | One source FDA |
| Wikidata | Q21098999 | elagolix | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C153373 | Elagolix | One source FDA |
| DrugBank | DB11979 | — | One source Wikidata |
Also registered as elagolix sodium (UNII 5948VUI423 · RxNorm 2049847).
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.